๐Ÿ”ฌ Third-party verified peptides ยท Free Express Post over $200 CAD
Pantheon Peptides
Brain & Nerve4 cited studies

Dihexa

Angiotensin IV-derived neuroplasticity compound studied for HGF/c-Met signaling and synapse formation.

Also known as: PNB-0408
SummaryMechanismDosingSafetyStudies
Research use only โ€” not for human consumption.

What it is

Dihexa (PNB-0408) is a peptide-like angiotensin IV derivative researched for neuroplasticity, learning and memory pathways, synaptic signaling, and cognitive resilience.

Mechanism of action

Dihexa is studied for hepatocyte growth factor (HGF)/c-Met-related signaling, a pathway involved in neuronal survival, dendritic branching, synapse formation, and repair responses.

Evidence summary

Evidence is preclinical and unsettled. Source literature includes rodent memory and synaptogenesis studies, but part of the foundational Dihexa literature includes a PubMed-listed retraction notice, so claims should be presented cautiously.

Typical dosing protocols

Typical dose
10000โ€“10000 mcg
Frequency
5x per week
Cycle length
4 weeks
  • Oral compound; no BAC water or injection calculation needed
  • 10 mg once daily
  • 5 days on / 2 days off for 2-4 weeks; morning is most common

Side effects & safety

  • Headache, nausea, digestive upset, restlessness, stimulation, or sleep disruption
  • Anxiety, irritability, mood changes, vivid dreams, or uncomfortable cognitive intensity
  • Avoid use in active or recent cancer unless supervised because HGF/c-Met is a growth-factor pathway
Contraindications
  • โ€ข Active or recent cancer without qualified clinician supervision
  • โ€ข Psychiatric instability or concerning neurological symptoms

Cited studies

  1. McCoy AT, et al. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics.
    Read source โ†—
  2. Wright JW, Harding JW (2015). The brain HGF/c-Met receptor system: a new target for Alzheimer's disease research. Journal of Alzheimer's Disease.
    PMID 25649658Read source โ†—
  3. (2022). Reduced HGF/MET signaling may contribute to synaptic pathology in an Alzheimer's disease mouse model. Frontiers in Aging Neuroscience.
    PMID 35903536Read source โ†—
  4. Benoist CC, et al. (2014). Procognitive and synaptogenic effects of AngIV-derived peptides and HGF/c-Met signaling. PubMed page includes 2025 retraction notice.
    PMID 25187433Read source โ†—
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.